Lutetium brain-sparing therapy for advanced gut and pancreas tumors
Part of Cancer clinical trials.
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old and can legally give informed consent.
- Your cancer is a low- or medium-grade gastrointestinal/pancreatic neuroendocrine tumor (G1 or G2) confirmed by tissue biopsy.
- Your overall health allows you to do normal daily activities (ECOG 0–1).
- Your tumor is locally advanced and cannot be removed by surgery or has spread to other parts of the body.
- You do not have known brain (CNS) metastases, or if you were treated for brain metastases before, scans must be stable for at least 24 weeks and you must have no symptoms.
- Your heart condition and blood sugar are well controlled, and you do not have severe urinary problems (like severe incontinence, fluid buildup in the kidney, major difficulty urinating, or a long-term urinary catheter).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
This study looks at outcomes for adults with tumors that are advanced (can’t be fully removed or has spread) and are getting worse, where tests show somatostatin receptors. It aims to understand how treatment with lutetium-177 helps people in this situation.
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
This trial tests a new radioactive drug (Lutetium-177 BL-ARC001) for people with advanced solid tumors, including stomach, bowel, and other cancers. It aims to see if the treatment is safe and how well it works.
This trial tests a radioactive drug called Lutathera for people with neuroendocrine tumors that are not in the stomach or intestines and can't be removed by surgery. The drug targets a specific receptor on the tumor cells to deliver radiation directly, which may help slow or shrink the cancer.
Hear when a new Advanced Gastroenteropancreatic Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.